HDAC9 and small cell lung carcinoma: However, HDAC inhibitors are generally inactive against SCLC as a monotherapy, with ORRs of 0% [106,107,108], while combinations with chemotherapy have high toxicity [109,110], except for belinostat with chemotherapy, which demonstrated acceptable toxicity and an ORR of 57% (Table 1) [111].